Leslie E. Priddy

Dedicated and highly skilled Scientist with 14 years of experience in miRNA mimic research, quality, diagnostics, drug development and discovery in oncology, and enzyme replacement therapeutics. Possess extensive expertise in the use of preclinical in vivo and in vitro models to conduct pharmacology studies, identify candidate drugs, and inform clinical development strategies. Successful track record of delivering strategies and data packages that have driven projects forward. Proficient in pharmacology, molecular biology, and cell biology skills including small animal surgery, dosing (IV, IP, PO, and IT), blood collection, necropsy, molecular analysis (RNA isolation, qRT-PCR, and ELISA), and cell biology methods (cell culture and transfection). Strong critical thinking, analytical, and organizational skills with proven abilities to manage multiple projects, priorities, deadlines, and stakeholders. Adept in designing/implementing studies, assaying for key endpoints, utilizing sophisticated methods for data analysis, generating and conducting oral presentations, and documenting results.

• Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer: Mol Cancer Ther (2014) 13 (10): 2352–2360.
• Combined Replenishment of miR-34a and let-7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models: Nano Small Molecule (2020) 16 (20): 1906426
• Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth: Cancer Immunol Res (2021) 9 (4): 415–429.